MedTrace Logo

Hyoscine Butylbromide for Prevention of Bradycardia During Cesarean Section

NCT04069078 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 173

Last updated 2020-03-03

No results posted yet for this study

Summary

The aim of this study is to assess the efficacy of Iv hyoscine butylbromide in preventing Bradycardia during cesarean section under spinal anaesthesia with local anaesthetic and morphine.

Conditions

  • Bradycardia
  • Spinal Anesthetics Causing Adverse Effects in Therapeutic Use
  • Cesarean Section Complications

Interventions

DRUG

Hyoscine Butylbromide 20 Mg/mL Solution for Injection Ampoule

Patients will receive IV study solution which is hyoscine butylbromide 20 mg in 1 ml one minute after spinal anaesthesia

OTHER

Normal saline

Patients will receive 1 ml of IV normal saline as a placebo one minute after spinal anesthesia

Sponsors & Collaborators

  • Assiut University

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
40 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-10-10
Primary Completion
2020-02-25
Completion
2020-02-25

Countries

  • Egypt

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04069078 on ClinicalTrials.gov